Select publications

• Monsen PJ, Bommi PV, Grigorescu AA, Lauing KL, Mao Y, Berardi P, Zhai L, Ojo O, Penco-Campillo M, Koch T, Egozi M, Jha SV, Dunne SF, Jiang H, Song G, Zhang F, Kregel S, Vaziri-Gohar A, Fanning S, Sanchez-Gomez P, Allen JM, Yamini B, Lukas RV, Wainwright DA, Schiltz GE. Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). bioRxiv. 2025 Jan 8. PubMed PMID: 39829781

• Rabin EE, Huang J, Kim M, Mozny A, Lauing KL, Penco-Campillo M, Zhai L, Bommi P, Mi X, Power EA, Prabhu VC, Anderson DE, Barton KP, Walunas TL, Schiltz GE, Amidei C, Sanchez-Gomez P, Thakkar JP, Lukas RV, Wainwright DA. Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma. Brain Behav Immun Health. 2024 Jul;38:100753. eCollection 2024 Jul. PubMed PMID: 38600951

• Johnson M, Bell A, Lauing KL, Ladomersky E, Zhai L, Penco-Campillo M, Shah Y, Mauer E, Xiu J, Nicolaides T, Drumm M, McCortney K, Elemento O, Kim M, Bommi P, Low JT, Memon R, Wu J, Zhao J, Mi X, Glantz MJ, Sengupta S, Castro B, Yamini B, Horbinski C, Baker DJ, Walunas TL, Schiltz GE, Lukas RV, Wainwright DA. Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clin Cancer Res. 2023 Dec 1;29(23):4973-4989. PubMed PMID: 37725593

• Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC, Matei DE, Bonini MG, Munshi HG, Hashizume R, Wu JD, Zhang B, James CD, Chen P, Kocherginsky M, Horbinski C, Cameron MD, Grigorescu AA, Yamini B, Lukas RV, Schiltz GE, Wainwright DA. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem. 2022 Dec 8;65(23):15642-15662.  Epub 2022 Nov 21. PubMed PMID: 36410047

• Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, Lauing KL, Alonso MM, Wainwright DA, Gomez-Manzano C, Fueyo J. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 Jul;10(7). PubMed PMID: 35902132

• Rabin EE, Kim M, Mozny A, Cardoza K, Bell AC, Zhai L, Bommi P, Lauing KL, King AL, Armstrong TS, Walunas TL, Fang D, Roy I, Peipert JD, Sieg E, Mi X, Amidei C, Lukas RV, Wainwright DA. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. Brain Behav Immun Health. 2022 May;21:100449. eCollection 2022 May. PubMed PMID: 35368609

• Zhai L, Ladomersky E, Lauing KL, Bollu L, Bell A, Kim M, Rabin E, Wainwright DA. Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy. In: Jackson C, Lim M, editors. Immunotherapeutic Strategies for the Treatment of Glioma [Internet] 1st ed. Sensitizing Agents for Cancer Resistant to Cell Mediated Immunotherapy: Elsevier; 2022. Chapter 8; p.127-151. 

• Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, Genet M, Kim M, Chen P, Mi X, Wu JD, Schipma MJ, Wray B, Griffiths J, Unwin RD, Clark SJ, Acharya R, Bao R, Horbinski C, Lukas RV, Schiltz GE, Wainwright DA. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 Dec 1;27(23):6514-6528. Epub 2021 Sep 3. PubMed PMID: 34479957.

• Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L, Rabin E, Dixit K, Kumthekar P, Platanias LC, Hou L, Zheng Y, Wu J, Zhang B, Hrachova M, Merrill SA, Mrugala MM, Prabhu VC, Horbinski C, James CD, Yamini B, Ostrom QT, Johnson MO, Reardon DA, Lukas RV, Wainwright DA. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021 Jan-Dec;3(1):vdab125. eCollection 2021 Jan-Dec. Review. PubMed PMID: 34647022.

Full publication record found here